TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
29.66
-0.85 (-2.79%)
At close: Feb 25, 2026, 4:00 PM EST
29.78
+0.12 (0.40%)
After-hours: Feb 25, 2026, 4:42 PM EST
TG Therapeutics Revenue
TG Therapeutics had revenue of $161.71M in the quarter ending September 30, 2025, with 92.79% growth. This brings the company's revenue in the last twelve months to $531.90M, up 100.88% year-over-year. In the year 2024, TG Therapeutics had annual revenue of $329.00M with 40.80% growth.
Revenue (ttm)
$531.90M
Revenue Growth
+100.88%
P/S Ratio
8.24
Revenue / Employee
$1,422,187
Employees
374
Market Cap
4.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
| Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
| Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
| Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
| Dec 31, 2020 | 152.00K | - | - |
| Dec 31, 2019 | 152.00K | - | - |
| Dec 31, 2018 | 152.00K | - | - |
| Dec 31, 2017 | 152.00K | - | - |
| Dec 31, 2016 | 152.00K | -381.00 | -0.25% |
| Dec 31, 2015 | 152.38K | - | - |
| Dec 31, 2014 | 152.38K | - | - |
| Dec 31, 2013 | 152.38K | 133.33K | 699.98% |
| Dec 31, 2012 | 19.05K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.05B |
| Amicus Therapeutics | 634.21M |
| ADMA Biologics | 488.56M |
| NewAmsterdam Pharma Company | 22.50M |
| CG Oncology | 2.17M |
| Crinetics Pharmaceuticals | 1.54M |
TGTX News
- 2 days ago - TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update - GlobeNewsWire
- 17 days ago - TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis - GlobeNewsWire
- 19 days ago - TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum - GlobeNewsWire
- 5 weeks ago - These under-the-radar stocks combine fast growth with big upside potential - Market Watch
- 5 weeks ago - TG Therapeutics: The "Exit Velocity" You Can't Ignore (Rating Upgrade) - Seeking Alpha
- 6 weeks ago - TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - TG Therapeutics Stock Climbs After The Bell: Here's Why - Benzinga
- 7 weeks ago - TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire